Calo Psychiatric Center Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Taiwan

Organization Overview

First Clinical Trial
2008
NCT03730857
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Calo Psychiatric Center

Active Ingredients

Drugs in Phase 2 Trials (1)

paliperidone (invega) (2 trials)

Drugs in Phase 1 Trials (3)

cassia seed (1 trial)

olanzapine (zyprexa) (1 trial)

risperidone (risperdal) (1 trial)

Drugs in Other Trials (1)

hawthorn berry extract (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Obesity (Phase 1)

Schizophrenia (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 5